Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 04, 2022

BUY
$8.63 - $15.52 $35,918 - $64,594
4,162 Added 23.76%
21,681 $192,000
Q2 2022

Jul 29, 2022

BUY
$8.59 - $20.77 $14,809 - $35,807
1,724 Added 10.91%
17,519 $221,000
Q1 2022

May 13, 2022

SELL
$15.52 - $35.65 $7,666 - $17,611
-494 Reduced 3.03%
15,795 $298,000
Q4 2021

Feb 09, 2022

BUY
$28.89 - $35.33 $9,995 - $12,224
346 Added 2.17%
16,289 $563,000
Q3 2021

Nov 02, 2021

BUY
$35.66 - $42.94 $91,075 - $109,668
2,554 Added 19.08%
15,943 $583,000
Q2 2021

Aug 03, 2021

SELL
$23.7 - $39.27 $32,279 - $53,485
-1,362 Reduced 9.23%
13,389 $525,000
Q1 2021

May 14, 2021

SELL
$27.01 - $36.8 $28,414 - $38,713
-1,052 Reduced 6.66%
14,751 $416,000
Q4 2020

Feb 12, 2021

BUY
$27.51 - $34.36 $39,174 - $48,928
1,424 Added 9.9%
15,803 $466,000
Q3 2020

Nov 13, 2020

BUY
$25.8 - $34.61 $38,880 - $52,157
1,507 Added 11.71%
14,379 $466,000
Q2 2020

Aug 14, 2020

BUY
$17.65 - $28.05 $38,582 - $61,317
2,186 Added 20.46%
12,872 $354,000
Q1 2020

May 14, 2020

SELL
$15.19 - $29.51 $84,790 - $164,724
-5,582 Reduced 34.31%
10,686 $190,000
Q4 2019

Feb 14, 2020

SELL
$17.17 - $25.95 $40,143 - $60,671
-2,338 Reduced 12.57%
16,268 $408,000
Q3 2019

Nov 14, 2019

SELL
$17.84 - $22.69 $107,842 - $137,161
-6,045 Reduced 24.52%
18,606 $332,000
Q2 2019

Aug 14, 2019

BUY
$22.0 - $31.78 $53,284 - $76,971
2,422 Added 10.9%
24,651 $542,000
Q1 2019

May 15, 2019

SELL
$21.27 - $30.58 $959,510 - $1.38 Million
-45,111 Reduced 66.99%
22,229 $680,000
Q4 2018

Feb 13, 2019

BUY
$23.09 - $37.69 $1.55 Million - $2.54 Million
67,340 New
67,340 $1.56 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Asset Management One Co., Ltd. Portfolio

Follow Asset Management One Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Asset Management One Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Asset Management One Co., Ltd. with notifications on news.